Wordt geladen...
Potential options for managing LOX+ ER− breast cancer patients
Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor negative (ER–) breast cancer patients with bone metastasis. In the present bioinformatics study, we observed that LOX is a prognostic factor for poor progression free survival in patients with ER– breast cancer. LOX overexp...
Bewaard in:
| Gepubliceerd in: | Oncotarget |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Impact Journals LLC
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5078060/ https://ncbi.nlm.nih.gov/pubmed/27147578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9073 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|